CluenexCorcept Therapeutics CORT
Corcept Therapeutics scores good on business quality (7.1 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Corcept Therapeutics does
Corcept Therapeutics develops pharmaceutical products that treat severe endocrine, oncological, and metabolic disorders, commercializing treatments like Korlym for Cushing's syndrome. Hospitals, clinics, and specialty pharmacies pay for these proprietary medications.
- What it does best
Corcept maintains elite pricing power and production efficiency, driving a gross margin of 98.3% that easily outpaces peers like BMY at 71.6%. This margin reflects proprietary drug formulations protected by dense patent walls that shield its core endocrinology portfolio from generic erosion.
- The main risk
Legal battles over patents for Korlym threaten its core revenue stream. If generic competitors invalidate key patents, a sudden drop in sales would crush cash flow and leave the company vulnerable to rapid top-line erosion.
Quality, check by check
Scored against its own industry, from company filings.
Operating margin is razor-thin at 0.7%, while FCF margin remains high at 45.0%. Operating profitability is currently compressed by heavy spending relative to gross profits, showing limited operating leverage at the current scale.
The regulatory moat rests on complex intellectual property protecting its cortisol modulators, locking in rare-disease patients and prescribing endocrinologists. Its gross margin ranks in the top decile of its sector at 99th percentile.
Revenue grew 12.7% to $831 million, powered by its core endocrinology segment. This rate shows moderation compared to earlier historical periods.
With zero total debt and $377 million in cash, the balance sheet is pristine. Free cash flow sits at $107 million, getting softer compared to prior years.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
3 sold $4.6M outside pre-planned sales.
Our sealed record on CORT
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Corcept Therapeutics scores good on the Cluenex quality check (7.1 of 10), measured against its own industry. Profitability is weak, moat strong, growth fast and financial health strong.
In the last 90 days of SEC Form 4 filings: 3 sold $4.6M outside pre-planned sales.
Nov 4, 2026.
See CORT today
- Today's verdict on CORT, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Corcept Therapeutics (CORT)”, https://cluenex.com/stocks/cort/, data as of Oct 10, 2026.